News

The rate of weight loss from onset to diagnosis can be a significant indicator of poorer outcomes among amyotrophic lateral sclerosis (ALS) patients, a study reports. The study, “Early weight loss in amyotrophic lateral sclerosis: outcome relevance and clinical correlates in a population-based cohort,” was published in the…

A human-derived antibody that specifically binds to abnormal superoxide dismutase 1 (SOD1) improved the symptoms and delayed disease progression in a mouse model for amyotrophic lateral sclerosis (ALS), a study shows. The antibody, alpha-miSOD1, could be further developed as a candidate treatment for ALS caused by SOD1 misfolding. The study titled…

In addition to symptoms of depression, disease progression is one of the strongest influences on health-related quality of life in amyotrophic lateral sclerosis (ALS) patients, a study reports. According to the study, titled Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis,” slower disease progression is linked to…

CuATSM, one of the lead investigational therapies of Collaborative Medicinal Development (CMD), may slow disease progression and improve the respiratory and cognitive function of patients with amyotrophic lateral sclerosis (ALS), a Phase 1 trial shows. The findings of the multicenter, open-label, dose-finding study (NCT02870634) were announced by…

EnClear Therapies, a biotech company developing a device to halt the progression of neurological diseases including amyotrophic lateral sclerosis (ALS), announced it has spun out from QurAlis, one of its founding companies.

CloudMedx plans to develop a computer analysis algorithm that will track the clinical progression of patients with amyotrophic lateral sclerosis (ALS) to predict treatment outcomes. This tool will be the result of a new collaboration between the healthcare artificial intelligence (AI) company and the Gregory W. Fulton…

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Revalesio’s experimental therapy RNS60 for people diagnosed with amyotrophic lateral sclerosis (ALS). A phase 2 trial is now recruiting participants. Fast Track designation is intended to shorten the time it takes for the…

A new method called Axon-seq allows researchers to analyze the content of messenger RNAs (mRNAs) in the motor neuron’s axons, the tips of the nerve cells that communicate with muscle cells, a new study reports. Using Axon-seq, researchers identified 121 mRNAs that are deregulated in ALS motor neurons, highlighting the new…

Difficulty in recognizing emotions may be a sign of changes in the frontal lobe of the brain and associated behavioral symptoms in patients with amyotrophic lateral sclerosis (ALS). The study with that finding, “Deficits in Emotion Recognition as Markers of Frontal Behavioral Dysfunction in Amyotrophic Lateral Sclerosis,”…

ALS News Today brought you daily coverage of important discoveries, treatment developments, clinical trials, and other events dealing with amyotrophic lateral sclerosis (ALS) throughout 2018. As a reminder of what mattered most to you in 2018, here are the 10 most-read articles of last year with a brief description…